India's TCG launches new CDMO arm stateside to meet the call for 'American-made' pandemic drugs
Thanks to 57,000 square feet of real estate in New Jersey and Virginia, a new CDMO arm of India’s TCG Lifesciences now has a US footprint and will use it to focus on efficient and cheap production of Covid-19 related medicines and other antiviral drugs.
Called TCG GreenChem, the new manufacturing subsidiary will operate out of 3,000 square feet of lab space in Virginia Commonwealth University’s Biotechnology Research Park and 54,000 square feet of lab and office space in Princeton’s South Corporate Center.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.